• Alexion Pharmaceuticals Inc., of Cheshire, Conn., raised total net proceeds of about $140 million after closing its previously announced public offering of 3.45 million common shares, which included 450,000 for the underwriters' full exercise of their overallotment option. All the stock was sold by Alexion at $43 per share. Goldman, Sachs & Co. and Morgan Stanley & Co. Inc. acted as joint book-running managers. Co-managers included Bear, Stearns & Co. Inc., Credit Suisse, Cowen and Co. LLC and Piper Jaffray & Co. (See BioWorld Today, Nov. 16, 2006.)

• Amgen Inc., of Thousand Oaks, Calif., said the U.S. District Court denied a request by Bridgewater, N.J.-based Ortho Biotech Products LP seeking an injunction against the 2006 Amgen portfolio contract. The lawsuit involves Amgen's sales discounts on Aranesp (darbepoetin alfa) to its best customers. Aranesp is approved for anemia associated with chronic kidney disease and for chemotherapy-induced anemia in patients with non-myeloid malignancies.

• Galapagos NV, of Mechelen, Belgium, extended the target discovery alliance between its service division, BioFocus DPI, and Cystic Fibrosis Foundation Therapeutics Inc. for 15 months. That agreement exceeds €800,000 (US$1 million) in research fees and builds further on the alliance initiated in April 2005. BioFocus DPI is applying its SilenceSelect adenoviral library and expertise in assay design to discover drug targets for cystic fibrosis therapies.

• Novavax Inc., of Malvern, Pa., filed a $100 million shelf registration statement to sell a blend of securities from time to time, including common or preferred stock, warrants or any combination thereof. The registration carries forward $42 million of securities un-issued under Novavax's December 2005 registration statement.

• Nventa Biopharmaceuticals Corp., of San Diego, said it expects to file an amendment to an investigational new drug application by the first quarter of 2007 to begin a Phase I trial of HspE7 plus adjuvant, pending the FDA's approval and receipt of adequate corporate funding. The company recently met with the agency to discuss the plan for a reformulated version of HspE7, which now is being combined with Poly-ICLC, an adjuvant that targets the Toll-like receptor 3 pathway. HspE7 is a therapeutic vaccine for human papillomavirus-related diseases.

• OctoPlus NV, of Leiden, the Netherlands, granted an exclusive license to OP-145 for chronic middle ear infection for the Korean market to Green Cross Corp., of Seoul, South Korea. The Phase II peptide is designed to break the recurring cycle of infection causing chronic middle ear infection. Terms of the deal call for Green Cross to make an up-front payment, milestone payments and pay royalties to OctoPlus, which will retain manufacturing rights to the bulk material.

• SemBioSys Genetics Inc., of Calgary, Alberta, entered an agreement to have its plant-produced insulin manufactured by Cangene Corp., of Winnipeg, Manitoba. The contract is part of SemBioSys' preparations for an investigational new drug application and the initiation of clinical trials, so Cangene will manufacture insulin for its preclinical and early stage clinical development.

No Comments